TP53mutations, expression and interaction networks in human cancers

Xiaosheng Wang; Qingrong Sun

doi:10.18632/oncotarget.13483

journal article Nov 21, 2016

TP53mutations, expression and interaction networks in human cancers

Xiaosheng Wang

Qingrong Sun

Oncotarget Vol. 8 No. 1 pp. 624-643 · Impact Journals, LLC

View at Publisher Save 10.18632/oncotarget.13483

Topics

No keywords indexed for this article. Browse by subject →

References

50

[1]

Harris "p53 mutations in human cancers" Science (1991) 10.1126/science.1905840

[2]

Olivier "TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes" Oncogene (2007) 10.1038/sj.onc.1210302

[3]

Thomas "The importance of p53 pathway genetics in inherited and somatic cancer genomes" Nature reviews Cancer (2016) 10.1038/nrc.2016.15

[4]

Drugging the p53 pathway: understanding the route to clinical efficacy

Kian Hoe Khoo, Chandra S. Verma, David P. Lane

Nature Reviews Drug Discovery 2014 10.1038/nrd4236

[5]

The first 30 years of p53: growing ever more complex

Arnold J. Levine, Moshe Oren

Nature Reviews Cancer 2009 10.1038/nrc2723

[6]

Hernandez "Pan-cancer patterns of somatic copy number alteration" Nat Genet (2013) 10.1038/ng.2760

[7]

Mutational landscape and significance across 12 major cancer types

Cyriac Kandoth, Michael D. McLellan, Fabio Vandin et al.

Nature 2013 10.1038/nature12634

[8]

The Cancer Genome Atlas Pan-Cancer analysis project

John N Weinstein, Eric A Collisson, Gordon B Mills et al.

Nature Genetics 2013 10.1038/ng.2764

[9]

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Patricia A.J. Muller, Karen H. Vousden

Cancer Cell 2014 10.1016/j.ccr.2014.01.021

[10]

Simon "Identification of potential synthetic lethal genes to p53 using a computational biology approach" BMC medical genomics (2013) 10.1186/1755-8794-6-30

[11]

Kaelin "The concept of synthetic lethality in the context of anticancer therapy" Nat Rev Cancer (2005) 10.1038/nrc1691

[12]

Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

Audrey Petitjean, Ewy Mathe, Shunsuke Kato et al.

Human Mutation 2007 10.1002/humu.20495

[13]

Prives "Transcriptional regulation by p53" Cold Spring Harbor perspectives in biology (2010)

[14]

Benchimol "Transcriptional repression mediated by the p53 tumour suppressor" Cell death and differentiation (2003) 10.1038/sj.cdd.4401191

[15]

Yarbrough "ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways" Cell (1998) 10.1016/s0092-8674(00)81401-4

[16]

Kim "Mitotic centromere-associated kinase (MCAK/Kif2C) regulates cellular senescence in human primary cells through a p53-dependent pathway" FEBS letters (2012) 10.1016/j.febslet.2012.10.012

[17]

Katagiri "Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis" Cancer science (2008) 10.1111/j.1349-7006.2007.00635.x

[18]

Groninger "Kinase inhibitors and monoclonal antibodies in oncology: clinical implications" Nature reviews Clinical oncology (2016) 10.1038/nrclinonc.2015.213

[19]

Lin "A novel Aurora-A-mediated phosphorylation of p53 inhibits its interaction with MDM2" Biochimica et biophysica acta (2013) 10.1016/j.bbapap.2012.11.005

[20]

Yen "p53-dependent apoptosis in response to spindle damage is linked to loss of Bub1" Cancer biology & therapy (2009) 10.4161/cbt.8.7.8140

[21]

Powers "Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability" Molecular cancer therapeutics (2010) 10.1158/1535-7163.mct-10-0095

[22]

Nakano "MELK-a conserved kinase: functions, signaling, cancer, and controversy" Clinical and translational medicine (2015) 10.1186/s40169-014-0045-y

[23]

Shieh "TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18" Molecular and cellular biology (2009) 10.1128/mcb.01837-08

[24]

Fukasawa "Transcriptional control of BubR1 by p53 and suppression of centrosome amplification by BubR1" Molecular and cellular biology (2005) 10.1128/mcb.25.10.4046-4061.2005

[25]

McDonnell "Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression" The Journal of biological chemistry (2006) 10.1074/jbc.m513901200

[26]

Thomas "Large-scale gene function analysis with the PANTHER classification system" Nature protocols (2013) 10.1038/nprot.2013.092

[27]

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

Aravind Subramanian, Pablo Tamayo, Vamsi K. Mootha et al.

Proceedings of the National Academy of Sciences 2005 10.1073/pnas.0506580102

[28]

Chen "The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression" Cold Spring Harbor perspectives in medicine (2016)

[29]

Poon "Stalled replication induces p53 accumulation through distinct mechanisms from DNA damage checkpoint pathways" Cancer research (2006) 10.1158/0008-5472.can-05-1790

[30]

Meek "p53-dependent repression of polo-like kinase-1 (PLK1)" Cell cycle (2010) 10.4161/cc.9.20.13532

[31]

Malek "A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer" Nature medicine (2016)

[32]

Poon "p53 deficiency enhances mitotic arrest and slippage induced by pharmacological inhibition of Aurora kinases" Oncogene (2014) 10.1038/onc.2013.325

[33]

Lespagnol "The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase" Proceedings of the National Academy of Sciences of the United States of America (2003) 10.1073/pnas.0530298100

[34]

You "p53 Transgenic mice are highly susceptible to 4-nitroquinoline-1-oxide-induced oral cancer" Molecular cancer research (2006) 10.1158/1541-7786.mcr-06-0028

[35]

Jensen "STRING v9. 1: protein-protein interaction networks, with increased coverage and integration" Nucleic Acids Res (2013)

[36]

Berchuck "Expression signatures of TP53 mutations in serous ovarian cancers" BMC Cancer (2010) 10.1186/1471-2407-10-237

[37]

Boyd "Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma" Gynecologic oncology (2004) 10.1016/j.ygyno.2004.01.043

[38]

Li "Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 >/= 1,000 U/mL" Scientific reports (2016) 10.1038/srep19222

[39]

Wang "Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis" International journal of colorectal disease (2011) 10.1007/s00384-011-1164-1

[40]

Bae "Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer" Ann Surg Oncol (2016)

[41]

Louis "Accumulation of wild type p53 protein in human astrocytomas" Cancer Res (1993)

[42]

Mayall "Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers" J Natl Cancer Inst (1992) 10.1093/jnci/84.11.845

[43]

Choppin "Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas" J Immunol (1998) 10.4049/jimmunol.160.1.328

[44]

Mazoyer "Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?" Human mutation (2008) 10.1002/humu.20590

[45]

Nonsense-Mediated RNA Decay Regulation by Cellular Stress: Implications for Tumorigenesis

Lawrence B. Gardner

Molecular Cancer Research 2010 10.1158/1541-7786.mcr-09-0502

[46]

Strigari "Prognostic role of serum p53 antibodies in lung cancer" BMC Cancer (2015) 10.1186/s12885-015-1174-4

[47]

He "Malignancy of Cancers and Synthetic Lethal Interactions Associated With Mutations of Cancer Driver Genes" Medicine (2016) 10.1097/md.0000000000002697

[48]

A Landscape of Pharmacogenomic Interactions in Cancer

Francesco Iorio, Theo A. Knijnenburg, Daniel J. Vis et al.

Cell 2016 10.1016/j.cell.2016.06.017

[49]

Mufti "Applying synthetic lethality for the selective targeting of cancer" N Engl J Med (2014) 10.1056/nejmra1407390

[50]

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Yoav Benjamini, Yosef Hochberg

Journal of the Royal Statistical Society Series B:... 1995 10.1111/j.2517-6161.1995.tb02031.x

Metrics

117

Citations

50

References

Details

Published: Nov 21, 2016
Vol/Issue: 8(1)
Pages: 624-643

Authors

X

Xiaosheng Wang

Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China

Q

Qingrong Sun

School of Science, China Pharmaceutical University, Nanjing 211198, China

Cite This Article

Xiaosheng Wang, Qingrong Sun (2016). TP53mutations, expression and interaction networks in human cancers. Oncotarget, 8(1), 624-643. https://doi.org/10.18632/oncotarget.13483

TP53mutations, expression and interaction networks in human cancers

You May Also Like